DK0956861T3 - Kombinationsterapi omfattende ribavirin og interferon-alfa til patienter med kronisk hepatitis C infektion, der ikke har modtaget antiviral behandling - Google Patents
Kombinationsterapi omfattende ribavirin og interferon-alfa til patienter med kronisk hepatitis C infektion, der ikke har modtaget antiviral behandlingInfo
- Publication number
- DK0956861T3 DK0956861T3 DK99303729T DK99303729T DK0956861T3 DK 0956861 T3 DK0956861 T3 DK 0956861T3 DK 99303729 T DK99303729 T DK 99303729T DK 99303729 T DK99303729 T DK 99303729T DK 0956861 T3 DK0956861 T3 DK 0956861T3
- Authority
- DK
- Denmark
- Prior art keywords
- interferon
- infection
- patients
- alpha
- chronic hepatitis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7956698A | 1998-05-15 | 1998-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0956861T3 true DK0956861T3 (da) | 2002-07-01 |
Family
ID=22151354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK99303729T DK0956861T3 (da) | 1998-05-15 | 1999-05-13 | Kombinationsterapi omfattende ribavirin og interferon-alfa til patienter med kronisk hepatitis C infektion, der ikke har modtaget antiviral behandling |
Country Status (23)
Country | Link |
---|---|
EP (3) | EP1213029A1 (ja) |
JP (2) | JP5281726B2 (ja) |
KR (1) | KR100694345B1 (ja) |
CN (1) | CN1230198C (ja) |
AR (1) | AR019551A1 (ja) |
AT (1) | ATE216591T1 (ja) |
AU (2) | AU766597B2 (ja) |
BR (1) | BR9910505A (ja) |
CA (1) | CA2331823A1 (ja) |
CZ (1) | CZ300540B6 (ja) |
DE (1) | DE69901321T2 (ja) |
DK (1) | DK0956861T3 (ja) |
ES (1) | ES2172288T3 (ja) |
HK (1) | HK1021131A1 (ja) |
HU (1) | HU230432B1 (ja) |
IL (3) | IL139220A0 (ja) |
MY (1) | MY129244A (ja) |
NO (1) | NO330715B1 (ja) |
NZ (1) | NZ507621A (ja) |
PT (1) | PT956861E (ja) |
SK (1) | SK288038B6 (ja) |
TW (1) | TWI277424B (ja) |
WO (1) | WO1999059621A1 (ja) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR021876A1 (es) * | 1998-12-18 | 2002-08-07 | Schering Corp | Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado |
SK8612002A3 (en) * | 1999-12-23 | 2003-03-04 | Ribapharm Inc | Compositions and methods for L-nucleosides, L-nucleotides, and their analogs |
JP4536194B2 (ja) * | 2000-02-17 | 2010-09-01 | 大日本住友製薬株式会社 | 安定な注射用製剤 |
JP2003530839A (ja) * | 2000-04-12 | 2003-10-21 | プリンシピア ファーマスーティカル コーポレイション | アルブミン融合タンパク質 |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
EA200601591A1 (ru) | 2000-05-26 | 2007-02-27 | Айденикс (Кайман) Лимитед | Применение рибонуклеозидных соединений для лечения флавивирусных и пестивирусных инфекций |
US20020127203A1 (en) * | 2000-10-18 | 2002-09-12 | Albrecht Janice K. | Ribavirin-pegylated interferon alfa HCV combination therapy |
US20030143197A1 (en) * | 2001-11-09 | 2003-07-31 | Moran S. Mark | Method for treating diseases with omega interferon |
EP2277910A1 (en) | 2001-12-21 | 2011-01-26 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
BR0312278A (pt) | 2002-06-28 | 2007-06-19 | Idenix Cayman Ltd | éster 2'-c-metil-3'-o-l-valina de ribofuranosil citidina para tratamento de infecções por flaviviridae |
BR0312271A (pt) | 2002-06-28 | 2007-11-06 | Idenix Cayman Ltd | compostos, composições e seus usos para o tratamento de infecções por flaviviridae |
DK1576138T3 (en) | 2002-11-15 | 2017-05-01 | Idenix Pharmaceuticals Llc | 2'-METHYL NUCLEOSIDES IN COMBINATION WITH INTERFERON AND FLAVIVIRIDAE MUTATION |
BRPI0408846A (pt) * | 2003-03-28 | 2006-07-04 | Pharmasset Inc | compostos para o tratamento de infecções por flaviviridae |
WO2004110392A2 (en) * | 2003-04-01 | 2004-12-23 | Intermune, Inc. | Compositions and methods for treating coronavirus infection and sars |
WO2004091653A1 (en) * | 2003-04-17 | 2004-10-28 | Ares Trading S.A. | Interferon beta in severe acute respiratory syndrome (sars) |
EP2345658A1 (en) | 2003-05-30 | 2011-07-20 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
US7482149B2 (en) * | 2003-06-09 | 2009-01-27 | Genome Institute Of Singapore | Inhibition of SARS coronavirus infection with clinically approved antiviral drugs |
WO2005016370A1 (en) * | 2003-08-13 | 2005-02-24 | Howard J. Smith & Associates Pty Ltd | Method of treating viral infections |
AR045870A1 (es) * | 2003-10-11 | 2005-11-16 | Vertex Pharma | Terapia de combinacion para la infeccion de virus de hepatitis c |
RU2433124C2 (ru) | 2004-09-14 | 2011-11-10 | Фармассет, Инк. | Способ получения 2'-фтор-2'-алкилзамещенных или других замещенных рибофуранозилпиримидинов и пуринов и их производных |
MY141025A (en) * | 2004-10-29 | 2010-02-25 | Vertex Pharma | Dose forms |
BRPI0706379A2 (pt) * | 2006-01-09 | 2011-03-22 | Romark Lab Lc | tratamento de hepatite viral |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
AU2008279087A1 (en) | 2007-07-25 | 2009-01-29 | Biolex Therapeutics, Inc. | Controlled release interferon drug products and treatment of HCV infection using same |
TW200946541A (en) | 2008-03-27 | 2009-11-16 | Idenix Pharmaceuticals Inc | Solid forms of an anti-HIV phosphoindole compound |
EP2376514A2 (en) | 2008-12-23 | 2011-10-19 | Pharmasset, Inc. | Nucleoside analogs |
PA8855801A1 (es) | 2008-12-23 | 2010-07-27 | Sintesis de nucleosidos de purina | |
AR074897A1 (es) | 2008-12-23 | 2011-02-23 | Pharmasset Inc | Fosforamidatos de nucleosidos |
EP2427213B1 (en) | 2009-05-08 | 2015-04-01 | Sciclone Pharmaceuticals, Inc. | Alpha thymosin peptides as vaccine enhancers |
TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
US8859756B2 (en) | 2010-03-31 | 2014-10-14 | Gilead Pharmasset Llc | Stereoselective synthesis of phosphorus containing actives |
MX2013003903A (es) * | 2010-10-05 | 2013-05-20 | Novartis Ag | Nuevos tratamientos de infeccion por el virus de hepatitis c. |
ES2716158T3 (es) | 2010-11-30 | 2019-06-10 | Gilead Pharmasset Llc | 2'-spiro-nucleótidos para el tratamiento de hepatitis C |
KR102198749B1 (ko) * | 2011-03-02 | 2021-01-06 | 제롬 쉔타그 | 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단 |
KR101991298B1 (ko) | 2011-09-16 | 2019-06-21 | 길리애드 파마셋 엘엘씨 | Hcv 치료 방법 |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
WO2014120981A1 (en) | 2013-01-31 | 2014-08-07 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
PL3038601T3 (pl) | 2013-08-27 | 2020-08-24 | Gilead Pharmasset Llc | Formulacja złożona dwóch związków przeciwwirusowych |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4211771A (en) | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
US4492537A (en) | 1982-12-10 | 1985-01-08 | Awerkamp John B | Fluid-operated oil or water well pump |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
JP2514950B2 (ja) | 1986-03-10 | 1996-07-10 | エフ・ホフマン―ラ ロシユ アーゲー | 化学修飾蛋白質,その製造法および中間体 |
US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
HUT75533A (en) | 1993-11-10 | 1997-05-28 | Schering Corp | Improved interferon polymer conjugates |
US5766582A (en) | 1994-10-11 | 1998-06-16 | Schering Corporation | Stable, aqueous alfa interferon solution formulations |
US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
JP2758154B2 (ja) | 1995-04-06 | 1998-05-28 | エフ・ホフマン−ラ ロシユ アーゲー | インターフェロンを含む液体製剤 |
US6387365B1 (en) * | 1995-05-19 | 2002-05-14 | Schering Corporation | Combination therapy for chronic hepatitis C infection |
US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
ES2214551T3 (es) * | 1995-11-02 | 2004-09-16 | Schering Corporation | Terapia de infusion continua de citocinas a baja dosis. |
TW517067B (en) | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
CA2298543A1 (en) | 1997-08-13 | 1999-02-25 | James Barry | Loading and release of water-insoluble drugs |
EP1136075B1 (en) * | 1997-09-21 | 2003-01-15 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
-
1999
- 1999-05-13 WO PCT/US1999/007037 patent/WO1999059621A1/en active Application Filing
- 1999-05-13 TW TW088107774A patent/TWI277424B/zh not_active IP Right Cessation
- 1999-05-13 IL IL13922099A patent/IL139220A0/xx unknown
- 1999-05-13 EP EP01130613A patent/EP1213029A1/en not_active Withdrawn
- 1999-05-13 AT AT99303729T patent/ATE216591T1/de active
- 1999-05-13 EP EP99303729A patent/EP0956861B1/en not_active Expired - Lifetime
- 1999-05-13 AU AU38600/99A patent/AU766597B2/en not_active Withdrawn - After Issue
- 1999-05-13 ES ES99303729T patent/ES2172288T3/es not_active Expired - Lifetime
- 1999-05-13 JP JP2000549285A patent/JP5281726B2/ja not_active Expired - Lifetime
- 1999-05-13 HU HU0103423A patent/HU230432B1/hu unknown
- 1999-05-13 CZ CZ20004177A patent/CZ300540B6/cs not_active IP Right Cessation
- 1999-05-13 CN CNB998085960A patent/CN1230198C/zh not_active Expired - Lifetime
- 1999-05-13 EP EP10181927A patent/EP2305287A1/en not_active Withdrawn
- 1999-05-13 DE DE69901321T patent/DE69901321T2/de not_active Expired - Lifetime
- 1999-05-13 CA CA002331823A patent/CA2331823A1/en not_active Abandoned
- 1999-05-13 PT PT99303729T patent/PT956861E/pt unknown
- 1999-05-13 MY MYPI99001891A patent/MY129244A/en unknown
- 1999-05-13 DK DK99303729T patent/DK0956861T3/da active
- 1999-05-13 KR KR1020007012784A patent/KR100694345B1/ko not_active IP Right Cessation
- 1999-05-13 SK SK1710-2000A patent/SK288038B6/sk not_active IP Right Cessation
- 1999-05-13 BR BR9910505-5A patent/BR9910505A/pt not_active Application Discontinuation
- 1999-05-14 AR ARP990102303A patent/AR019551A1/es unknown
- 1999-11-20 HK HK99105377A patent/HK1021131A1/xx not_active IP Right Cessation
-
2000
- 2000-10-18 NZ NZ507621A patent/NZ507621A/xx not_active IP Right Cessation
- 2000-10-23 IL IL139220A patent/IL139220A/en not_active IP Right Cessation
- 2000-11-14 NO NO20005755A patent/NO330715B1/no not_active IP Right Cessation
-
2005
- 2005-10-10 AU AU2005220271A patent/AU2005220271B9/en not_active Expired
-
2010
- 2010-07-27 IL IL207259A patent/IL207259A/en not_active IP Right Cessation
-
2011
- 2011-04-07 JP JP2011085606A patent/JP2011173898A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0956861T3 (da) | Kombinationsterapi omfattende ribavirin og interferon-alfa til patienter med kronisk hepatitis C infektion, der ikke har modtaget antiviral behandling | |
NO20031742L (no) | HCV-kombinasjonsterapi med ribavirin og pegylert interferon alfa | |
DK1087778T3 (da) | Anvendelse af PEG-IFN-alfa og Ribavirin til behandling af kronisk hepatitis C | |
NO20015059D0 (no) | HCV-kombinasjonsterapi, inneholdende ribavirin i assosiasjon med antioksydanter | |
NO995263L (no) | Konjugater av polyetylenglykol og interferon-<alfa> for terapi av infeksjoner | |
DK0903148T3 (da) | Kombinationsterapi til udryddelse af påviselig HCV-RNA hos patienter med kronisk hepatitis C infektion | |
ZA988466B (en) | Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection | |
WO2000037110A3 (en) | Ribavirin-pegylated interferon alfa induction hcv combination therapy | |
MY127670A (en) | Pegylated interferon alfa-ccr5 antagonists combination hiv therapy | |
DK0980254T3 (da) | Farmaceutisk antiviruspræparat omfattende glycyrrhizinsyre og mindst et protein udstyret med antiviral aktivitet | |
ID24910A (id) | Karboksilat nukleosid hemisulfat dan penggunaan dalam perlakuan infeksi viral | |
WO2000051631A3 (en) | Pegylated alpha interferon for hiv therapy | |
DK1311279T3 (da) | Behandling af hepatitis C med thymosin, interferon og ribavirin | |
DK1311286T3 (da) | Behandling af hepatitis C med thymosin og pegyleret interferon | |
SI1311279T1 (sl) | Zdravljenje hepatitisa c s timozinom, interferonom in ribavirinom | |
DK0704100T3 (da) | Elektronisk styre- og udløserteknik til anbringelse i munden, især til personer med fysisk handicap | |
PT9467T (pt) | Perfil pes de mesa, cadeira e banco | |
ES1032267Y (es) | Faja perfeccionada aplicable en enfermmos operados de colostomia. | |
TH58469A3 (th) | การใช้ Peg-IFN-อัลฟา และไรบาวิริน สำหรับการบำบัดตับอักเสบ C เรื้อรัง |